MASLD in type 2 diabetes: steatosis–fibrosis burden and metabolic determinants in a real-world cohort
Acta Diabetologica · 2026
DOI: 10.1007/s00592-026-02791-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2026. Verfasst von Salvatore Corrao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Relevance and High Specialisation Hospital Trust ARNAS Civico Di Cristina Benfratelli, Palermo, 90127, Ital…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Fatty Liver. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in type 2 diabetes mellitus (T2DM), but the burden of steatosis and fibrosis and their associated factors remain incompletely defined. We assessed the prevalence, severity, and factors associated with of MASLD in a real-world cohort of patients with T2DM.
Methods
In this cross-sectional study, 219 consecutive outpatients with T2DM underwent anthropometric laboratory, ultrasonographic and shear-wave elastographic assessment. MASLD was defined by the multisociety Delphi consensus. Independent associations were evaluated using multivariable logistic regression, with waist circumference as the primary adiposity measure.
Results
MASLD was diagnosed in 75.3% of participants. Severe steatosis (S3) was present in 11.9%, clinically significant fibrosis (F ≥ 2) in 7.3%, and advanced fibrosis (F ≥ 3) in 5.5%. Male sex (OR 2.49, 95% CI 1.26–4.94) and waist circumference (OR 1.04 per cm, 95% CI 1.01–1.07) were independently associated with MASLD. Severe steatosis was independently associated with male sex and waist circumference. MASLD prevalence increased across waist circumference quartiles (trend p = 0.001), while the adjusted odds plateaued in the upper half, paralleled by a higher prevalence of severe steatosis ( p < 0.001), whereas fibrosis was not associated with abdominal adiposity ( p = 0.65). HbA1c and diabetes duration did not differ between groups in univariable comparisons, and age was not associated with MASLD in the multivariable models.
Conclusions
MASLD is highly prevalent in T2DM and is independently associated with male sex and central adiposity. Abdominal adiposity identifies steatosis risk in a graded manner but does not discriminate fibrosis, supporting adiposity- and sex-informed hepatic phenotyping in patients with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, National Relevance and High Specialisation Hospital Trust ARNAS Civico Di Cristina Benfratelli, Palermo, 90127, Italy. salvatore.corrao@unipa.it.
- Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, Palermo, 90127, Italy. salvatore.corrao@unipa.it.
- Department of Clinical Medicine and Head of Internal Medicine Unit, National Relevance and High Specialisation Hospital Trust ARNAS Ospedale Civico, P.zza Nicola Leotta, 4, Palermo, 90127, Italy. salvatore.corrao@unipa.…
- Department of Internal Medicine, National Relevance and High Specialisation Hospital Trust ARNAS Civico Di Cristina Benfratelli, Palermo, 90127, Italy.
- Institute for Biomedical Research and Innovation, National Research Council (IRIB-CNR), Palermo, Italy.
- Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialities (PROMISE), University of Palermo, Palermo, 90127, Italy.
Förderung
- Università degli Studi di Palermo
Zitieren
APA
Corrao, S., Scibetta, S., Bongiorno, B., Lopriore, C., Calvo, L., & Local Outpatient Registry Investigators (LOR-i) (2026). MASLD in type 2 diabetes: steatosis–fibrosis burden and metabolic determinants in a real-world cohort. Acta Diabetologica. https://doi.org/10.1007/s00592-026-02791-5
Vancouver
Corrao S, Scibetta S, Bongiorno B, Lopriore C, Calvo L, Local Outpatient Registry Investigators (LOR-i). MASLD in type 2 diabetes: steatosis–fibrosis burden and metabolic determinants in a real-world cohort. Acta Diabetologica. 2026. doi:10.1007/s00592-026-02791-5
BibTeX
@article{Corrao2026,
author = {Corrao, Salvatore and Scibetta, Salvatore and Bongiorno, Brenda and Lopriore, Carola and Calvo, Luigi and Local Outpatient Registry Investigators (LOR-i), Local Outpatient Registry Investigators (LOR-i)},
title = {MASLD in type 2 diabetes: steatosis–fibrosis burden and metabolic determinants in a real-world cohort},
journal = {Acta Diabetologica},
year = {2026},
doi = {10.1007/s00592-026-02791-5}
}
EUVIMED